Inhibrx Biosciences, Inc. (INBX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$105.57

From 52W high−22.91%

Volume468143.00

Market cap$1.61B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$105.57

From 52W high

−22.91%

Volume

468143.00

Market cap

$1.61B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.3x

P/E (TTM)

—

RSI (14)

49.1

MomentumView details →

1D Return

+4.41%

YTD Return

+35.88%

SummaryUpdated Jun 1, 2026

Inhibrx Biosciences, Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company founded in 2024 and based in La Jolla, California. The company went public on June 4, 2024, representing a spinoff from its parent company Inhibrx, Inc. Inhibrx Biosciences focuses on developing innovative biologic therapeutics for patients with life-threatening conditions, particularly in oncology. The company operates as a pure-play biotechnology firm dedicated to advancing two primary drug candidates through clinical trials.

Ask drillr about Inhibrx Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−12.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−30.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

260.83%

ROA (TTM)

−89.60%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+17.78%

FCF YoY

+5.90%

Revenue CAGR 3Y

−15.98%

EPS CAGR 3Y

—

EBITDA YoY

+22.33%

MomentumView details →

1D Return

+4.41%

YTD Return

+35.88%

1Y Return

+288.93%

RSI (14)

49.1

vs 50D SMA

+8.19%

vs 200D SMA

+19.04%

Capital & dividendView details →

Debt/Equity

−0.10x

Current Ratio

5.07x

Quick Ratio

5.07x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$2.34

EPS Surprise

−2.63%

Beats (12Q)

4/12

Next Q EPS Est

−$2.45

Avg Surprise (4Q)

−1.10%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−138.18M

Op. CF (TTM)

−131.89M

Next earningsNov 13, 2026 →

Latest newsMore news →

Inhibrx announced that its experimental OX40-targeting immunotherapy showed responses in patients with head and neck cancer, particularly in a subset with HPV-positive tumors.12d ago

Inhibrx entered into an amended loan agreement with Oxford Finance, expanding the total facility to $500.0 million and receiving an initial $100.0 million tranche.66d ago

Similar companies

Mabpharm Limited02181.HK Eton Pharmaceuticals, Inc.ETON AnaptysBio, Inc.ANAB Forte Biosciences, Inc.FBRX Taysha Gene Therapies, Inc.TSHA Syndax Pharmaceuticals, Inc.SNDX Find similar companies →

Latest newsMore news →

Inhibrx announced that its experimental OX40-targeting immunotherapy showed responses in patients with head and neck cancer, particularly in a subset with HPV-positive tumors.12d ago Inhibrx entered into an amended loan agreement with Oxford Finance, expanding the total facility to $500.0 million and receiving an initial $100.0 million tranche.66d ago